MGNX
Macrogenics Inc
Halal Rating :
Last Price
$3.00
Last updated:
Market Cap
-
7D Change
-5.36%
1 Year Change
-75.23%
Company Overview
Industries
Exchange
Next Earnings Date
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company's main products include MARGENZA, approved for the treatment of adult patients with metastatic HER2-positive breast cancer, and several other product candidates in various stages of clinical development.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $110.71m | $56.52m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $10.8m | $68.98m | - | $6000.0 | 0.00% | 0.01% |
| March 31, 2024 | $9.1m | $63.99m | - | $1.13m | 0.00% | 1.77% |
Company Impact
Help us evaluate Macrogenics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.